You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
迪哲醫藥(688192.SH):舒沃哲和高瑞哲克服非小細胞肺癌耐藥的研究進展獲選2025年歐洲肺癌大會報告
格隆匯 03-20 16:40

格隆匯3月20日丨迪哲醫藥(688192.SH)公佈,公司將於3月28日在2025年歐洲肺癌大會(ELCC)報告其自主研發的兩款源頭創新藥物舒沃哲(通用名:舒沃替尼片)和高瑞哲(通用名:戈利昔替尼膠囊)分別針對晚期非小細胞肺癌(NSCLC)靶向和免疫治療耐藥的最新研究進展。

舒沃哲是一款針對多種表皮生長因子受體(EGFR)突變亞型的高選擇性EGFR酪氨酸激酶抑制劑(TKI),於2023年8月通過優先審評在中國獲批上市,用於EGFR20號外顯子插入突變(Exon20ins)NSCLC的二/後線治療。高瑞哲是一款高選擇性JAK1抑制劑,於2024年6月通過優先審評在中國獲批上市,用於復發/難治外周T細胞淋巴瘤(r/rPTCL)的治療。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account